专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007070488A2 INTEGRIN ALPHA L I DOMAIN MUTANTS WITH INCREASED BINDING AFFINITY 审中-公开
标题翻译： INTEGRIN ALPHA L I DOMAIN MUTANTS WITH INCREASING BINDING AFFINITY
公开(公告)号：WO2007070488A2
公开(公告)日：2007-06-21
申请号：PCT/US2006/047281
申请日：2006-12-12
申请人： THE CBR INSTITUTE FOR BIOMEDICAL RESEARCH, INC. , JIN, Moonsoo , SPRINGER, Timothy
发明人： JIN, Moonsoo , SPRINGER, Timothy
IPC分类号： C07K14/705
CPC分类号： C07K14/70546 , A61K38/00
摘要： The present invention provides an isolated polypeptide capable of binding to ªCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a method for inhibiting ICAM-I and a pharmaceutical composition comprising an integrin (XL I domain polypeptide or biologically active portion of the polypeptides. The invention also provides a method of treating or preventing an LFA-I mediated ICAM-l associated disease such as inflammation, artherosclerosis, allograft rejection, diabetes, T-cell mediated sensitization reaction, psoriasis, HIV infection, or rheumatoid arthritis.
摘要翻译：本发明提供能够结合至-CAM-1的分离的多肽，其包含整合素（XL I结构域或其生物活性部分，其中一个或多个残基被取代，其中取代的多肽以比野生型更高的亲和力结合ICAM-1 本发明提供了一种抑制ICAM-1的方法和包含整联蛋白（XL I结构域多肽或多肽的生物活性部分）的药物组合物，本发明还提供了一种治疗或预防LFA-1介导的方法 ICAM-1相关疾病如炎症，动脉粥样硬化，同种异体移植排斥，糖尿病，T细胞介导的致敏反应，牛皮癣，HIV感染或类风湿性关节炎。

2. 发明申请

WO2007070488A3 INTEGRIN ALPHA L I DOMAIN MUTANTS WITH INCREASED BINDING AFFINITY 审中-公开
标题翻译： INTEGRIN ALPHA L I DOMAIN MUTANTS WITH INCREASING BINDING AFFINITY
公开(公告)号：WO2007070488A3
公开(公告)日：2008-06-26
申请号：PCT/US2006047281
申请日：2006-12-12
申请人： CBR INST FOR BIOMED RES INC , JIN MOONSOO , SPRINGER TIMOTHY
发明人： JIN MOONSOO , SPRINGER TIMOTHY
IPC分类号： C07K14/00 , C07H21/04
CPC分类号： C07K14/70546 , A61K38/00
摘要： The present invention provides an isolated polypeptide capable of binding to ªCAM-1, comprising the integrin (XL I domain or biologically active portion thereof, wherein one or more residues is substituted, wherein the substituted polypeptide binds ICAM-I at a higher affinity than wild type integrin CCL protein. The invention provides a method for inhibiting ICAM-I and a pharmaceutical composition comprising an integrin (XL I domain polypeptide or biologically active portion of the polypeptides. The invention also provides a method of treating or preventing an LFA-I mediated ICAM-l associated disease such as inflammation, artherosclerosis, allograft rejection, diabetes, T-cell mediated sensitization reaction, psoriasis, HIV infection, or rheumatoid arthritis.
摘要翻译：本发明提供能够结合至-CAM-1的分离的多肽，其包含整合素（XL I结构域或其生物活性部分，其中一个或多个残基被取代，其中取代的多肽以比野生型更高的亲和力结合ICAM-1 本发明提供了一种抑制ICAM-1的方法和包含整联蛋白（XL I结构域多肽或多肽的生物活性部分）的药物组合物，本发明还提供了一种治疗或预防LFA-1介导的方法 ICAM-1相关疾病如炎症，动脉粥样硬化，同种异体移植排斥，糖尿病，T细胞介导的致敏反应，牛皮癣，HIV感染或类风湿性关节炎。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式